ESLA

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

Wall Street analysts forecast ESLA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESLA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Estrella Immunopharma Inc revenue for the last quarter amounts to -4.80M USD, increased 922.54 % YoY.

Estrella Immunopharma Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

Estrella Immunopharma Inc (ESLA) has 0 emplpoyees as of December 15 2025.

Today ESLA has the market capitalization of 65.33M USD.